Meta Biomed Co., Ltd. (KOSDAQ:059210)
South Korea · Delayed Price · Currency is KRW 3,530.00
-10.00 (-0.28%)
At close: Jun 10, 2026
Meta Biomed Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 9,781 | 10,988 | 22,402 | 10,080 | 2,628 | 9,522 |
Depreciation & Amortization | 5,737 | 5,499 | 4,981 | 4,223 | 3,860 | 3,571 |
Loss (Gain) From Sale of Assets | -638.09 | -588.13 | 0.91 | -12.62 | -1,212 | -1,160 |
Asset Writedown & Restructuring Costs | 707.61 | 707.61 | - | 1,015 | 487.37 | 541.23 |
Loss (Gain) From Sale of Investments | 493.15 | 7.68 | -349.53 | -90.29 | -53.65 | -51.16 |
Loss (Gain) on Equity Investments | 535.96 | -308.09 | -1,181 | -682.88 | -373.09 | -537.62 |
Provision & Write-off of Bad Debts | -253.28 | -204.72 | 444.66 | -158.44 | -172.39 | -1,376 |
Other Operating Activities | 9,300 | 9,657 | -1,456 | -2,926 | 2,115 | -1,637 |
Change in Accounts Receivable | -3,269 | -4,199 | 597.84 | 186.61 | -1,024 | -171.24 |
Change in Inventory | -6,418 | -4,532 | -2,514 | -470.44 | 926.99 | 2,038 |
Change in Accounts Payable | 304.18 | 145.12 | -807.66 | 304.05 | 93.14 | -1,503 |
Change in Other Net Operating Assets | 782.9 | 2,661 | 513.17 | -1,251 | 1,884 | 1,900 |
Operating Cash Flow | 17,064 | 19,833 | 22,633 | 10,217 | 9,159 | 11,136 |
Operating Cash Flow Growth | -21.40% | -12.37% | 121.52% | 11.55% | -17.75% | 129.06% |
Capital Expenditures | -18,468 | -20,304 | -10,914 | -11,489 | -15,395 | -2,067 |
Sale of Property, Plant & Equipment | 15.56 | 88.77 | 61.83 | 128.06 | 7.45 | 1,413 |
Cash Acquisitions | - | - | - | - | -2,295 | -2.45 |
Divestitures | 8.32 | 8.32 | - | - | - | 535.01 |
Sale (Purchase) of Intangibles | -154.31 | -156.74 | -188.9 | -5.43 | 85.95 | -33.29 |
Investment in Securities | 14,481 | 13,330 | -32,421 | 1,116 | -167.9 | 6,349 |
Other Investing Activities | -3,231 | -35.43 | 98.4 | -1,451 | 3,186 | 130 |
Investing Cash Flow | -6,849 | -6,569 | -43,363 | -11,701 | -14,578 | 6,324 |
Long-Term Debt Issued | - | 18,500 | 60,700 | 11,375 | 37,083 | 1,949 |
Long-Term Debt Repaid | - | -25,465 | -36,544 | -11,940 | -27,828 | -17,827 |
Net Debt Issued (Repaid) | -5,153 | -6,965 | 24,156 | -565.37 | 9,255 | -15,878 |
Repurchase of Common Stock | - | - | -140.74 | - | -63.26 | - |
Dividends Paid | - | -684.93 | -457.42 | -457.42 | -458.02 | -229.01 |
Other Financing Activities | -2,120 | -2,115 | -148 | -0 | - | 0 |
Financing Cash Flow | -7,273 | -9,764 | 23,410 | -1,023 | 8,734 | -16,107 |
Foreign Exchange Rate Adjustments | 1,491 | -60.76 | 1,041 | 77.02 | -201.36 | 121.38 |
Miscellaneous Cash Flow Adjustments | -0 | -0 | 0 | - | -0 | 0 |
Net Cash Flow | 4,434 | 3,439 | 3,721 | -2,430 | 3,113 | 1,474 |
Free Cash Flow | -1,405 | -471.17 | 11,719 | -1,271 | -6,236 | 9,069 |
Free Cash Flow Growth | - | - | - | - | - | 244.28% |
Free Cash Flow Margin | -1.41% | -0.46% | 12.46% | -1.53% | -9.04% | 15.43% |
Free Cash Flow Per Share | -53.86 | -18.77 | 432.22 | -55.59 | -272.48 | 396.00 |
Cash Interest Paid | 1,412 | 1,552 | 2,094 | 2,176 | 1,259 | 733.31 |
Cash Income Tax Paid | 1,437 | 889.59 | 163.57 | 80 | 379.03 | 357.43 |
Levered Free Cash Flow | -13,869 | -14,442 | 6,742 | -3,338 | -6,175 | 5,650 |
Unlevered Free Cash Flow | -12,398 | -12,663 | 9,081 | -1,891 | -5,306 | 6,366 |
Change in Working Capital | -8,599 | -5,926 | -2,211 | -1,231 | 1,880 | 2,263 |